184: Phase I Study of Bortezomib, (BTZ) followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL)
Year: 2008
Type: article
Study design: Clinical Trial
Abstract: Background: Novel treatment approaches are paramount for patients with primary refractory MM and PCL, because despite HD chemotherapy, patient median survival is approximately 12 months. The proteasome inhibitor BTZ sensitizes myeloma cells to melphalan both in vitro and in vivo by a mechanism not well understood. In this study we examine the effects of BTZ, followed by BTZ and HD Mel as conditioning regimen for TanPSCT in this poor-risk group. Methods: Patients with primary refractory MM or PCL received 2 cycles of BTZ at 1.3 mg/m2.
Institution: Moffitt Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,650
OpenAlex ID: W1969285538